Correction to: association of the matrix metalloproteinases (MMPs) family gene polymorphisms and the risk of coronavirus disease 2019 (COVID-19); implications of contribution for development of neurological symptoms in the COVID-19 patients.

Correction to: Molecular Biology Reports (2023) 50:173–183. In the original form of the published article, the criteria for detection of neurologic syndrome in the COVID-19 subjects is missing. Initially, 500 subjects with COVID-19 were recruited, among which 72 patients were diagnosed as having neurologic syndrome. The diagnosis was accomplished by a neurologist using a complete examination that involved several approaches: Clinical assessment. Detailed history: Information about the patient’s medical history, including any pre-existing neurological conditions were collected. Symptom evaluation: The presence and nature of neurological symptoms, such as headache, delirium, dizziness, confusion, muscle weakness, and altered sensation were assessed. Physical examination: Neurological examination: A thorough neurological examination was performed to assess motor function, sensory function, reflexes, coordination, and cranial nerve function. Diagnostic tests: Imaging: Neuroimaging technique (brain MRI) was used to identify structural abnormalities, such as strokes, encephalitis, or other lesions. Electroencephalogram (EEG): EEG was recorded to detect abnormal brain electrical activity, such as seizures or encephalopathy.